ASRS 2019 Street Team: Raj K. Maturi, MD

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.

Related Videos
How to diagnose geographic atrophy earlier
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Related Content
© 2023 MJH Life Sciences

All rights reserved.